BiotechTube

simvastatin + placebo

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carotid Artery Disease

Conditions

Carotid Artery Disease

Trial Timeline

Sep 1, 2002 → Mar 1, 2006

NCT ID
NCT00587717

About simvastatin + placebo

simvastatin + placebo is a pre-clinical stage product being developed by Merck for Carotid Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00587717. Target conditions include Carotid Artery Disease.

What happened to similar drugs?

3 of 6 similar drugs in Carotid Artery Disease were approved

Approved (3) Terminated (1) Active (2)
🔄RosuvastatinAstraZenecaPhase 3
✅Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mgAstraZenecaApproved
✅Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved
✅EvolocumabAmgenApproved
❌Rimonabant + Placebo (for Rimonabant)SanofiPhase 3
🔄Gadobutrol (Gadovist, BAY86-4875)BayerPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT00935259Phase 1Completed
NCT00321802Phase 2Completed
NCT00486044Phase 2Completed
NCT00588471Pre-clinicalTerminated
NCT00704314Pre-clinicalCompleted
NCT00587717Pre-clinicalCompleted

Competing Products

9 competing products in Carotid Artery Disease

See all competitors
ProductCompanyStageHype Score
AbciximabEli LillyPhase 1/2
24
RosuvastatinAstraZenecaPhase 3
40
Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mgAstraZenecaApproved
39
Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved
43
Atorvastatin/niacin extended-release + Atorvastatin + Simvastatin + SimvastatinMerckPhase 2
35
EvolocumabAmgenApproved
39
Atorvastatin - Cholestyramine - SitosterolPfizerPre-clinical
26
Rimonabant + Placebo (for Rimonabant)SanofiPhase 3
32
Gadobutrol (Gadovist, BAY86-4875)BayerPhase 3
37